ITHACA, N.Y.--(BUSINESS WIRE)--Vybion, Inc. was awarded a contract by P2D in Cincinnati as part of collaboration on an SBIR Phase II grant. Vybion is developing a humanized version of the monoclonal antibody genes, developing the expression lines and the process for manufacturing the product. The antibody, specific for cocaine, binds cocaine in the blood stream, causing cocaine in brain tissues to cross the blood brain barrier back into the blood where it remains bound to the antibody prior to detoxification in liver.
